Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer

Azevedo, Carla; Thuler, Luiz Cláudio Santos; Mello, Maria Júlia Gonçalves de; Lima, Jurema Telles de Oliveira; Fonte, Ana Luiza Fassizoli da; Fontao, Diogenes; Carneiro, Vandré Cabral Gomes; Chang, Tien Man; Ferreira, Carlos Gil

doi:10.1016/j.ygyno.2017.07.006

Cited by 44 publications

(40 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result reminded us that RCC patients with thrombus might not benefit from non-adjuvant therapy on the survival outcomes. A neoadjuvant chemotherapy study in cervical cancer reported a worsening of 1 and 3 years PFS but a better 5-year disease-free survival in neoadjuvant chemotherapy group (58.3 vs. 41.8%; p = 0.001) [25]. We found a negative result in both RFS and OS in our work.…”

Section: Discussionsupporting

confidence: 49%

Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus

et al. 2018

View full text Add to dashboard Cite

Objectives: The purpose of this work was to investigate the effect of sorafenib or sunitinib as neoadjuvant therapy on the survival outcomes of renal cell carcinoma (RCC) with tumor thrombus. Methods: A total of 92 RCC patients with tumor thrombus were included in this 2-center retrospective research from January 2007 to December 2014. Sorafenib and sunitinib were administered as neoadjuvant therapy in 9 patients and 14 patients, respectively, and 69 patients constituted non-neoadjuvant therapy groups. The Kaplan-Meier method was used to estimate the recurrence-free survival (RFS) and overall survival (OS). Log-rank test was used to compare the survival outcomes of patients with or without neoadjuvant therapy. Results: The overall median RFS and OS time for all 92 patients were 28 months (95% CI 17–39 months) and 42 months (95% CI 30–54 months). Patients with neoadjuvant therapy had no significantly longer median RFS (30 vs. 28 months, p = 0.376) and OS (45 vs. 42 months, p = 0.702) than those without neoadjuvant therapy. Conclusions: Neoadjuvant therapy of sorafenib or sunitinib might not improve survival outcomes for high risk RCC patients with tumor thrombus. Thus, neoadjuvant therapy for RCC with tumor thrombus should be considered cautiously.

show abstract

Section: Discussionsupporting

confidence: 49%

Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus

et al. 2018

View full text Add to dashboard Cite

show abstract

“…More than 65% of patients in both matched groups received induction chemotherapy, although current evidence did not support a survival benefit. 36 The rationale is that most of our patients were not detected by Pap smear because of lack of universal screening, so compared with those early-stage cervical cancers detected by Pap smear, the tumors in this study were relatively large. Induction chemotherapy may reduce tumor volume and radiation dose while controlling micrometastatic disease in this patient population with a relatively late diagnosis.…”

Section: Discussionmentioning

confidence: 95%

Comparison of Nedaplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients: A Propensity Score Analysis

Zhang

Nie

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…However, the role of NAC in CCRT has not been identified in LACC. Recent phase II trial did not show any meaningful improvement in treatment outcome [35]. The INTERLACE study (UK-funded) is an ongoing phase III trial of weekly induction CTx (carboplatin and paclitaxel) followed by standard CCRT compared to standard CCRT alone.…”

Section: Delivery Of Chemotherapy To Enhance Treatment Results In Laccmentioning

confidence: 99%

Management for locally advanced cervical cancer: new trends and controversial issues

Cho

Chun

2018

Radiat Oncol J

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 254This article reviewed new trends and controversial issues, including the intensification of chemotherapy and recent brachytherapy (BT) advances, and also reviewed recent consensuses from different societies on the management of locally advanced cervical cancer (LACC). Intensive chemotherapy during and after radiation therapy (RT) was not recommended as a standard treatment due to severe toxicities reported by several studies. The use of positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) for pelvic RT planning has increased the clinical utilization of intensity-modulated radiation therapy (IMRT) for the evaluation of pelvic lymph node metastasis and pelvic bone marrow. Recent RT techniques for LACC patients mainly aim to minimize toxicities by sparing the normal bladder and rectum tissues and shortening the overall treatment time by administering a simultaneous integrated boost for metastatic pelvic lymph node in pelvic IMRT followed by MRI-based image guided adaptive BT.

show abstract

Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer

Cited by 44 publications

References 29 publications

Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus

Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus

Comparison of Nedaplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients: A Propensity Score Analysis

Management for locally advanced cervical cancer: new trends and controversial issues

Contact Info

Product

Resources

About